XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.1
OTHER EXPENSE, NET
 12 Months Ended
Dec. 31, 2021
Other Income and Expenses [Abstract]  
OTHER EXPENSE, NET OTHER EXPENSE, NET
Other expense, net for the years 2021, 2020 and 2019 consists of:
(in millions)202120202019
Litigation and other matters$356 $422 $1,401 
Acquired in-process research and development costs8 32 41 
Net gain on sales of assets(2)(1)(31)
Acquisition-related contingent consideration11 48 20 
Other, net— 1 (5)
Other expense, net$373 $502 $1,426 
In 2021, Litigation and other matters of $356 million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, “LEGAL PROCEEDINGS”.
In 2020 and 2019, Acquired in-process research and development costs of $32 million and $41 million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements.
In 2019, Net gain on sales of assets includes $20 million related to the achievement of a milestone related to a certain product.